Trial
NCT01741155
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
—
Condition
Non Small Cell Lung Cancer (NSCLC)
Intervention
SPI-1620
Why stopped
The study did not meet efficacy end point and did not enroll patients in the randomized phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-13